BD&L
Navigator

Rapidly and accurately identify and prioritize external assets for specific areas of interest

BD&L Navigator

Identify assets, programs, and companies applying meaningful criteria. Place in context with the broader clinical development landscape and competing programs

Gain deeper insights on what drives the probability of success for identified assets and programs

BD&L Navigator
BD&L Navigator

Track the emerging trends clinical and preclinical research and correlate these to historic likelihood of success, as well as investment flows

Customer Use Case

  • Objective
  • Intelligencia's Advantage
  • Impact
Download PDF

Objective

The Business Development team at a top-20 pharmaceutical company had doubled down on its efforts to identify first-in-class drugs across two Therapeutic Areas: Oncology and Inflammation/Immunology.

Previously, the company had relied on extensive research to create a funnel of potential opportunities. It had also reviewed benchmarks on the probability of success for certain drug classes.

Objective

The Business Development team at a top-20 pharmaceutical company had doubled down on its efforts to identify first-in-class drugs across two Therapeutic Areas: Oncology and Inflammation/Immunology.

Previously, the company had relied on extensive research to create a funnel of potential opportunities. It had also reviewed benchmarks on the probability of success for certain drug classes.

Intelligencia's Advantage

Intelligencia’s BD&L Navigator applies ML-driven predictive analytics on a rich, expertly curated proprietary database to enable users to:

  • Identify promising programs, based on Probability of Success (e.g., transition to clinical stage, transition across phases, and/or regulatory approval)
  • Assess drug and program characteristics (e.g., first-in-class, time to completion, etc.)
  • Understand key drivers of drug development success
  • Review analogues and benchmarks

Impact

+80%

Accuracy (sensitivity and specificity) in assessing the probability of success of programs as early as in Ph1

+60%

Faster scanning and assessment of market opportunities

+15%

Increase in additional programs reviewed compared to business-as-usual methods
Download PDF